Requires certain NJ FamilyCare providers to provide information to, and obtain consent form from, parent or guardian of child that provider is prescribing antipsychotic drug.

This bill (A 919) requires NJ FamilyCare providers to share specific information with parents or guardians before prescribing psychotropic drugs (like stimulants, anti-anxiety, or anti-psychotic medications) to children under 18 enrolled in the program. Providers must give the drug’s FDA-approved Medication Guide, details on evidence-based treatment alternatives, and instructions for accessing FDA safety reporting tools (like MedWatch). They must then obtain a signed consent form confirming parents understand risks, alternatives, and how to report side effects, and retain this form in the child’s medical record. The law directly affects NJ FamilyCare providers and the parents/guardians of minor patients receiving these medications.